CME Group price target raised to $169 from $161 at Rosenblatt

Rosenblatt raised the firm’s price target on CME Group to $169 from $161 and keeps a Sell rating on the shares. The firm raised its Q2 EPS estimate to $2.25 to account for better than expected trading activity, noting that the Street is at $2.11 per share, but it maintains a Sell rating on the name given a “sector high” EBITDA multiple, its view that volumes may have peaked for the year and potential competition in rates from the FMX launch.